Skip to main content

Table 1 Disease was reduced in EE treated WT and ERKO mice compared to their respective controls.

From: GPR30, but not estrogen receptor-α, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol

   CDI Onset Peak
WT: Ctrl 64.5 (± 2.5) 12.3 (± 0.4) 5.1 (± 0.1)
  EE 54.0* (± 1.8) 12.0 (± 0.5) 4.8 (± 0.1)
ERKO: Ctrl 60.5 (± 4.0) 11.7 (± 0.4) 4.8 (± 0.2)
  EE 48.5* (± 3.1) 12.2 (± 0.4) 4.2* (± 0.2)
GPR30KO: Ctrl 47.6 (± 5.3) 11.5 (± 0.4) 4.5 (± 0.3)
  EE 51.2 (± 4.2) 11.0 (± 0.4) 4.6 (± 0.6)
  1. Cumulative disease index (CDI) was reduced in EE-WT and EE-ERKO mice compared to their respective control groups. Peak disease severity was only reduced in ERKO-EE mice. Onset did not differ between any EE and control groups. * indicates p < .03